Intro -- Halftitle Page -- Title Page -- Copyright Page -- Dedication -- Contents -- Acknowledgments -- Foreword -- Preface -- Part I: Apostles From the World of Medicine -- A Courageous Defender of Life: Jérôme Lejeune -- A Doctor of Love: John Billings -- Father of the Pro-Life Movement: Jack Willke -- The Last Renaissance Man: Karl Stern -- The Stubborn Insistence on Being Human: Wanda Poltawska -- The Wisdom of Nature: Herbert Ratner -- The Blessings and Challenges of Life: Eugene Diamond -- A Man of Graciousness: Walker Percy -- Part II: Apostles From the World of Philosophy -- A Man of Leonine Character: Dietrich von Hildebrand -- Finally Fitting In: Mortimer Adler -- The Inextinguishable Light: Saint Thomas Aquinas -- The Peasant Philosopher: Jacques Maritain -- To Love and Be Loved: Jean Vanier -- Truth and Timeliness: Josef Pieper -- An Adventure in Faith: Father Adam Exner -- The Making of a Philosopher: Stephen Schwarz -- Part III: Apostles From the World of Theology -- A Gentle Man of Firm Conviction: Cardinal John O'Connor -- A True Feminist: Saint Teresa Benedicta of the Cross -- An Apostle of Truth: Pope Benedict XVI -- Hope for a Beleaguered World: Saint Teresa of Kolkata -- John Paul the Great: Saint John Paul II -- All of the Same Heart: The Immortal Chaplains -- Dissenting From the Dissenters: William May -- A Minister for Life: Father Richard Neuhaus -- Part IV: Apostles From the World of Literature and Music -- A Man of Faith: Marshall McLuhan -- The Long Road to Conversion: Malcolm Muggeridge -- The Man Who Was Not a Child of His Age: G. K. Chesterton -- The Nearness of God: C. S. Lewis -- Reverence for Life: Whittaker Chambers -- The Tranquil Blossom: Joaquín Rodrigo -- The Silver-Tongued Orator: Alan Keyes -- A Pro-life Celebrity: Ben Stein -- Part V: Apostles From the World of Sports and Entertainment.
Access options:
The following links lead to the full text from the respective local libraries:
Conflict of interest statementAK reports grants from European Union 7th Framework Program during the conduct of the study. ADM has nothing to disclose. CM has nothing to disclose. AW has nothing to disclose. ES has nothing to disclose. ME reports grants from European Union 7th Framework Program during the conduct of the study. THC has nothing to disclose. MEn reports grants from European Union 7th Framework Program during the conduct of the study, grants from Bayer and fees paid to the Charité from Bayer, Boehringer Ingelheim, BMS/Pfizer, Daiichi Sankyo, Amgen, GlaxoSmithKlineGSK, Sanofi, Covidien, Novartis, all outside the submitted work. JBF reports grants from European Union 7th Framework Program during the conduct of the study and personal fees from Bioclinica, BMS, Biogen, Artemida, Cerevast, Guerbet, EISAI and Nicolab outside the submitted work. JF has nothing to disclose. IG reports grants from European Union 7th Framework Program during the conduct of the study. JP has nothing to disclose. VT reports grants from European Union 7th Framework Program and personal fees and non-financial support from Boehringer Ingelheim, Pfizer/BMS, Bayer, Sygnis, Amgen and Allergan outside the submitted work. RL reports no personal fees, but institutional support for consultancy and speaker fees from Bayer, Boehringer-Ingelheim, Genentech, Ischemaview, Medtronic and Occlutech outside the submitted work. KWM reports grants from European Union 7th Framework Program during the conduct of the study, personal fees and non-financial support from Boehringer Ingelheim outside the submitted work, personal fees from Boehringer Ingelheim, Bayer, Daiichi Sankyo and ReNeuron outside the submitted work. NN has nothing to disclose. SP reports grants from European Union 7th Framework Program during the conduct of the study. CZS reports grants from Novo Nordisk Foundation and personal fees from Bayer outside the submitted work. CG reports grants from European Union 7th Framework Program during the conduct of the study, personal fees from AMGEN, Bayer Vital, BMS, Boehringer Ingelheim, Sanofi Aventis, Abbott, and Prediction Biosciences outside the submitted work. GT reports grants from European Union 7th Framework Program during the conduct of the study, personal fees from Acandis, Boehringer Ingelheim, BMS/Pfizer, Stryker, Daiichi Sankyo, grants and personal fees from Bayer, grants from Corona Foundation, German Innovation Fonds and Else Kroener Fresenius Foundation outside the submitted work. BC reports grants from European Union 7th Framework Program during the conduct of the study and personal fees from Bayer Vital and Abbott, all outside the submitted work. ; International audience ; Stroke has a deleterious impact on quality of life. However, it is less well known if stroke lesions in different brain regions are associated with reduced quality of life (QoL). We therefore investigated this association by multivariate lesion-symptom mapping. We analyzed magnetic resonance imaging and clinical data from the WAKE-UP trial. European Quality of Life 5 Dimensions (EQ-5D) 3 level questionnaires were completed 90 days after stroke. Lesion symptom mapping was performed using a multivariate machine learning algorithm (support vector regression) based on stroke lesions 22-36 h after stroke. Brain regions with significant associations were explored in reference to white matter tracts. Of 503 randomized patients, 329 were included in the analysis (mean age 65.4 years, SD 11.5; median NIHSS = 6, IQR 4-9; median EQ-5D score 90 days after stroke 1, IQR 0-4, median lesion volume 3.3 ml, IQR 1.1-16.9 ml). After controlling for lesion volume, significant associations between lesions and EQ-5D score were detected for the right putamen, and internal capsules of both hemispheres. Multivariate lesion inference analysis revealed an association between injuries of the cortico-spinal tracts with worse self-reported quality of life 90 days after stroke in comparably small stroke lesions, extending previous reports of the association of striato-capsular lesions with worse functional outcome. Our findings are of value to identify patients at risk of impaired QoL after stroke.
Conflict of interest statementAK reports grants from European Union 7th Framework Program during the conduct of the study. ADM has nothing to disclose. CM has nothing to disclose. AW has nothing to disclose. ES has nothing to disclose. ME reports grants from European Union 7th Framework Program during the conduct of the study. THC has nothing to disclose. MEn reports grants from European Union 7th Framework Program during the conduct of the study, grants from Bayer and fees paid to the Charité from Bayer, Boehringer Ingelheim, BMS/Pfizer, Daiichi Sankyo, Amgen, GlaxoSmithKlineGSK, Sanofi, Covidien, Novartis, all outside the submitted work. JBF reports grants from European Union 7th Framework Program during the conduct of the study and personal fees from Bioclinica, BMS, Biogen, Artemida, Cerevast, Guerbet, EISAI and Nicolab outside the submitted work. JF has nothing to disclose. IG reports grants from European Union 7th Framework Program during the conduct of the study. JP has nothing to disclose. VT reports grants from European Union 7th Framework Program and personal fees and non-financial support from Boehringer Ingelheim, Pfizer/BMS, Bayer, Sygnis, Amgen and Allergan outside the submitted work. RL reports no personal fees, but institutional support for consultancy and speaker fees from Bayer, Boehringer-Ingelheim, Genentech, Ischemaview, Medtronic and Occlutech outside the submitted work. KWM reports grants from European Union 7th Framework Program during the conduct of the study, personal fees and non-financial support from Boehringer Ingelheim outside the submitted work, personal fees from Boehringer Ingelheim, Bayer, Daiichi Sankyo and ReNeuron outside the submitted work. NN has nothing to disclose. SP reports grants from European Union 7th Framework Program during the conduct of the study. CZS reports grants from Novo Nordisk Foundation and personal fees from Bayer outside the submitted work. CG reports grants from European Union 7th Framework Program during the conduct of the study, personal fees from AMGEN, Bayer Vital, BMS, Boehringer Ingelheim, Sanofi Aventis, Abbott, and Prediction Biosciences outside the submitted work. GT reports grants from European Union 7th Framework Program during the conduct of the study, personal fees from Acandis, Boehringer Ingelheim, BMS/Pfizer, Stryker, Daiichi Sankyo, grants and personal fees from Bayer, grants from Corona Foundation, German Innovation Fonds and Else Kroener Fresenius Foundation outside the submitted work. BC reports grants from European Union 7th Framework Program during the conduct of the study and personal fees from Bayer Vital and Abbott, all outside the submitted work. ; International audience ; Stroke has a deleterious impact on quality of life. However, it is less well known if stroke lesions in different brain regions are associated with reduced quality of life (QoL). We therefore investigated this association by multivariate lesion-symptom mapping. We analyzed magnetic resonance imaging and clinical data from the WAKE-UP trial. European Quality of Life 5 Dimensions (EQ-5D) 3 level questionnaires were completed 90 days after stroke. Lesion symptom mapping was performed using a multivariate machine learning algorithm (support vector regression) based on stroke lesions 22-36 h after stroke. Brain regions with significant associations were explored in reference to white matter tracts. Of 503 randomized patients, 329 were included in the analysis (mean age 65.4 years, SD 11.5; median NIHSS = 6, IQR 4-9; median EQ-5D score 90 days after stroke 1, IQR 0-4, median lesion volume 3.3 ml, IQR 1.1-16.9 ml). After controlling for lesion volume, significant associations between lesions and EQ-5D score were detected for the right putamen, and internal capsules of both hemispheres. Multivariate lesion inference analysis revealed an association between injuries of the cortico-spinal tracts with worse self-reported quality of life 90 days after stroke in comparably small stroke lesions, extending previous reports of the association of striato-capsular lesions with worse functional outcome. Our findings are of value to identify patients at risk of impaired QoL after stroke.
Conflict of interest statementAK reports grants from European Union 7th Framework Program during the conduct of the study. ADM has nothing to disclose. CM has nothing to disclose. AW has nothing to disclose. ES has nothing to disclose. ME reports grants from European Union 7th Framework Program during the conduct of the study. THC has nothing to disclose. MEn reports grants from European Union 7th Framework Program during the conduct of the study, grants from Bayer and fees paid to the Charité from Bayer, Boehringer Ingelheim, BMS/Pfizer, Daiichi Sankyo, Amgen, GlaxoSmithKlineGSK, Sanofi, Covidien, Novartis, all outside the submitted work. JBF reports grants from European Union 7th Framework Program during the conduct of the study and personal fees from Bioclinica, BMS, Biogen, Artemida, Cerevast, Guerbet, EISAI and Nicolab outside the submitted work. JF has nothing to disclose. IG reports grants from European Union 7th Framework Program during the conduct of the study. JP has nothing to disclose. VT reports grants from European Union 7th Framework Program and personal fees and non-financial support from Boehringer Ingelheim, Pfizer/BMS, Bayer, Sygnis, Amgen and Allergan outside the submitted work. RL reports no personal fees, but institutional support for consultancy and speaker fees from Bayer, Boehringer-Ingelheim, Genentech, Ischemaview, Medtronic and Occlutech outside the submitted work. KWM reports grants from European Union 7th Framework Program during the conduct of the study, personal fees and non-financial support from Boehringer Ingelheim outside the submitted work, personal fees from Boehringer Ingelheim, Bayer, Daiichi Sankyo and ReNeuron outside the submitted work. NN has nothing to disclose. SP reports grants from European Union 7th Framework Program during the conduct of the study. CZS reports grants from Novo Nordisk Foundation and personal fees from Bayer outside the submitted work. CG reports grants from European Union 7th Framework Program during the conduct of the study, personal fees from ...
Conflict of interest statementAK reports grants from European Union 7th Framework Program during the conduct of the study. ADM has nothing to disclose. CM has nothing to disclose. AW has nothing to disclose. ES has nothing to disclose. ME reports grants from European Union 7th Framework Program during the conduct of the study. THC has nothing to disclose. MEn reports grants from European Union 7th Framework Program during the conduct of the study, grants from Bayer and fees paid to the Charité from Bayer, Boehringer Ingelheim, BMS/Pfizer, Daiichi Sankyo, Amgen, GlaxoSmithKlineGSK, Sanofi, Covidien, Novartis, all outside the submitted work. JBF reports grants from European Union 7th Framework Program during the conduct of the study and personal fees from Bioclinica, BMS, Biogen, Artemida, Cerevast, Guerbet, EISAI and Nicolab outside the submitted work. JF has nothing to disclose. IG reports grants from European Union 7th Framework Program during the conduct of the study. JP has nothing to disclose. VT reports grants from European Union 7th Framework Program and personal fees and non-financial support from Boehringer Ingelheim, Pfizer/BMS, Bayer, Sygnis, Amgen and Allergan outside the submitted work. RL reports no personal fees, but institutional support for consultancy and speaker fees from Bayer, Boehringer-Ingelheim, Genentech, Ischemaview, Medtronic and Occlutech outside the submitted work. KWM reports grants from European Union 7th Framework Program during the conduct of the study, personal fees and non-financial support from Boehringer Ingelheim outside the submitted work, personal fees from Boehringer Ingelheim, Bayer, Daiichi Sankyo and ReNeuron outside the submitted work. NN has nothing to disclose. SP reports grants from European Union 7th Framework Program during the conduct of the study. CZS reports grants from Novo Nordisk Foundation and personal fees from Bayer outside the submitted work. CG reports grants from European Union 7th Framework Program during the conduct of the study, personal fees from AMGEN, Bayer Vital, BMS, Boehringer Ingelheim, Sanofi Aventis, Abbott, and Prediction Biosciences outside the submitted work. GT reports grants from European Union 7th Framework Program during the conduct of the study, personal fees from Acandis, Boehringer Ingelheim, BMS/Pfizer, Stryker, Daiichi Sankyo, grants and personal fees from Bayer, grants from Corona Foundation, German Innovation Fonds and Else Kroener Fresenius Foundation outside the submitted work. BC reports grants from European Union 7th Framework Program during the conduct of the study and personal fees from Bayer Vital and Abbott, all outside the submitted work. ; International audience ; Stroke has a deleterious impact on quality of life. However, it is less well known if stroke lesions in different brain regions are associated with reduced quality of life (QoL). We therefore investigated this association by multivariate lesion-symptom mapping. We analyzed magnetic resonance imaging and clinical data from the WAKE-UP trial. European Quality of Life 5 Dimensions (EQ-5D) 3 level questionnaires were completed 90 days after stroke. Lesion symptom mapping was performed using a multivariate machine learning algorithm (support vector regression) based on stroke lesions 22-36 h after stroke. Brain regions with significant associations were explored in reference to white matter tracts. Of 503 randomized patients, 329 were included in the analysis (mean age 65.4 years, SD 11.5; median NIHSS = 6, IQR 4-9; median EQ-5D score 90 days after stroke 1, IQR 0-4, median lesion volume 3.3 ml, IQR 1.1-16.9 ml). After controlling for lesion volume, significant associations between lesions and EQ-5D score were detected for the right putamen, and internal capsules of both hemispheres. Multivariate lesion inference analysis revealed an association between injuries of the cortico-spinal tracts with worse self-reported quality of life 90 days after stroke in comparably small stroke lesions, extending previous reports of the association of striato-capsular lesions with worse functional outcome. Our findings are of value to identify patients at risk of impaired QoL after stroke.
Conflict of interest statementAK reports grants from European Union 7th Framework Program during the conduct of the study. ADM has nothing to disclose. CM has nothing to disclose. AW has nothing to disclose. ES has nothing to disclose. ME reports grants from European Union 7th Framework Program during the conduct of the study. THC has nothing to disclose. MEn reports grants from European Union 7th Framework Program during the conduct of the study, grants from Bayer and fees paid to the Charité from Bayer, Boehringer Ingelheim, BMS/Pfizer, Daiichi Sankyo, Amgen, GlaxoSmithKlineGSK, Sanofi, Covidien, Novartis, all outside the submitted work. JBF reports grants from European Union 7th Framework Program during the conduct of the study and personal fees from Bioclinica, BMS, Biogen, Artemida, Cerevast, Guerbet, EISAI and Nicolab outside the submitted work. JF has nothing to disclose. IG reports grants from European Union 7th Framework Program during the conduct of the study. JP has nothing to disclose. VT reports grants from European Union 7th Framework Program and personal fees and non-financial support from Boehringer Ingelheim, Pfizer/BMS, Bayer, Sygnis, Amgen and Allergan outside the submitted work. RL reports no personal fees, but institutional support for consultancy and speaker fees from Bayer, Boehringer-Ingelheim, Genentech, Ischemaview, Medtronic and Occlutech outside the submitted work. KWM reports grants from European Union 7th Framework Program during the conduct of the study, personal fees and non-financial support from Boehringer Ingelheim outside the submitted work, personal fees from Boehringer Ingelheim, Bayer, Daiichi Sankyo and ReNeuron outside the submitted work. NN has nothing to disclose. SP reports grants from European Union 7th Framework Program during the conduct of the study. CZS reports grants from Novo Nordisk Foundation and personal fees from Bayer outside the submitted work. CG reports grants from European Union 7th Framework Program during the conduct of the study, personal fees from AMGEN, Bayer Vital, BMS, Boehringer Ingelheim, Sanofi Aventis, Abbott, and Prediction Biosciences outside the submitted work. GT reports grants from European Union 7th Framework Program during the conduct of the study, personal fees from Acandis, Boehringer Ingelheim, BMS/Pfizer, Stryker, Daiichi Sankyo, grants and personal fees from Bayer, grants from Corona Foundation, German Innovation Fonds and Else Kroener Fresenius Foundation outside the submitted work. BC reports grants from European Union 7th Framework Program during the conduct of the study and personal fees from Bayer Vital and Abbott, all outside the submitted work. ; International audience ; Stroke has a deleterious impact on quality of life. However, it is less well known if stroke lesions in different brain regions are associated with reduced quality of life (QoL). We therefore investigated this association by multivariate lesion-symptom mapping. We analyzed magnetic resonance imaging and clinical data from the WAKE-UP trial. European Quality of Life 5 Dimensions (EQ-5D) 3 level questionnaires were completed 90 days after stroke. Lesion symptom mapping was performed using a multivariate machine learning algorithm (support vector regression) based on stroke lesions 22-36 h after stroke. Brain regions with significant associations were explored in reference to white matter tracts. Of 503 randomized patients, 329 were included in the analysis (mean age 65.4 years, SD 11.5; median NIHSS = 6, IQR 4-9; median EQ-5D score 90 days after stroke 1, IQR 0-4, median lesion volume 3.3 ml, IQR 1.1-16.9 ml). After controlling for lesion volume, significant associations between lesions and EQ-5D score were detected for the right putamen, and internal capsules of both hemispheres. Multivariate lesion inference analysis revealed an association between injuries of the cortico-spinal tracts with worse self-reported quality of life 90 days after stroke in comparably small stroke lesions, extending previous reports of the association of striato-capsular lesions with worse functional outcome. Our findings are of value to identify patients at risk of impaired QoL after stroke.
Conflict of interest statementAK reports grants from European Union 7th Framework Program during the conduct of the study. ADM has nothing to disclose. CM has nothing to disclose. AW has nothing to disclose. ES has nothing to disclose. ME reports grants from European Union 7th Framework Program during the conduct of the study. THC has nothing to disclose. MEn reports grants from European Union 7th Framework Program during the conduct of the study, grants from Bayer and fees paid to the Charité from Bayer, Boehringer Ingelheim, BMS/Pfizer, Daiichi Sankyo, Amgen, GlaxoSmithKlineGSK, Sanofi, Covidien, Novartis, all outside the submitted work. JBF reports grants from European Union 7th Framework Program during the conduct of the study and personal fees from Bioclinica, BMS, Biogen, Artemida, Cerevast, Guerbet, EISAI and Nicolab outside the submitted work. JF has nothing to disclose. IG reports grants from European Union 7th Framework Program during the conduct of the study. JP has nothing to disclose. VT reports grants from European Union 7th Framework Program and personal fees and non-financial support from Boehringer Ingelheim, Pfizer/BMS, Bayer, Sygnis, Amgen and Allergan outside the submitted work. RL reports no personal fees, but institutional support for consultancy and speaker fees from Bayer, Boehringer-Ingelheim, Genentech, Ischemaview, Medtronic and Occlutech outside the submitted work. KWM reports grants from European Union 7th Framework Program during the conduct of the study, personal fees and non-financial support from Boehringer Ingelheim outside the submitted work, personal fees from Boehringer Ingelheim, Bayer, Daiichi Sankyo and ReNeuron outside the submitted work. NN has nothing to disclose. SP reports grants from European Union 7th Framework Program during the conduct of the study. CZS reports grants from Novo Nordisk Foundation and personal fees from Bayer outside the submitted work. CG reports grants from European Union 7th Framework Program during the conduct of the study, personal fees from ...
